Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety profile and the Maximum Tolerated Dose
(MTD) of TAK-901 in adult patients with advanced solid tumors or lymphoma. This study will
help to identify the recommended phase 2 dose and infusion duration, and describe the
pharmacokinetics of TAK-901.